BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 932 filers reported holding BAXTER INTL INC in Q1 2023. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,587,580 | -32.9% | 280,540 | -19.0% | 0.20% | -29.0% |
Q2 2023 | $15,786,540 | +85.1% | 346,500 | +64.8% | 0.28% | +75.8% |
Q1 2023 | $8,526,726 | +3960.3% | 210,225 | +6317.1% | 0.16% | +3925.0% |
Q2 2022 | $210,000 | -17.3% | 3,276 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $254,000 | -9.6% | 3,276 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $281,000 | +6.8% | 3,276 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $263,000 | -0.4% | 3,276 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $264,000 | -4.3% | 3,276 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $276,000 | +4.9% | 3,276 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $263,000 | 0.0% | 3,276 | 0.0% | 0.00% | -20.0% |
Q3 2020 | $263,000 | -6.7% | 3,276 | 0.0% | 0.01% | -16.7% |
Q2 2020 | $282,000 | +6.0% | 3,276 | 0.0% | 0.01% | -14.3% |
Q1 2020 | $266,000 | +10.8% | 3,276 | +13.9% | 0.01% | +75.0% |
Q4 2019 | $240,000 | -55.1% | 2,876 | -52.9% | 0.00% | -42.9% |
Q3 2019 | $534,000 | +8.3% | 6,105 | +1.5% | 0.01% | +16.7% |
Q2 2019 | $493,000 | +0.8% | 6,014 | 0.0% | 0.01% | -14.3% |
Q1 2019 | $489,000 | +23.5% | 6,014 | 0.0% | 0.01% | +16.7% |
Q4 2018 | $396,000 | -10.0% | 6,014 | +5.3% | 0.01% | 0.0% |
Q3 2018 | $440,000 | -19.6% | 5,714 | -22.9% | 0.01% | -14.3% |
Q2 2018 | $547,000 | +15.2% | 7,407 | +1.4% | 0.01% | +16.7% |
Q1 2018 | $475,000 | -4.4% | 7,303 | -5.0% | 0.01% | 0.0% |
Q4 2017 | $497,000 | -15.9% | 7,691 | -18.3% | 0.01% | -14.3% |
Q3 2017 | $591,000 | +5.5% | 9,412 | +1.8% | 0.01% | 0.0% |
Q2 2017 | $560,000 | +21.5% | 9,242 | +3.9% | 0.01% | +16.7% |
Q1 2017 | $461,000 | +21.6% | 8,898 | +4.1% | 0.01% | +20.0% |
Q4 2016 | $379,000 | -18.8% | 8,548 | -12.8% | 0.01% | -16.7% |
Q3 2016 | $467,000 | -44.8% | 9,807 | -47.6% | 0.01% | +20.0% |
Q2 2016 | $846,000 | -39.5% | 18,714 | -45.1% | 0.01% | -73.7% |
Q1 2016 | $1,399,000 | -4.9% | 34,064 | -11.7% | 0.02% | -5.0% |
Q4 2015 | $1,471,000 | +24.1% | 38,564 | +6.9% | 0.02% | +25.0% |
Q3 2015 | $1,185,000 | -53.0% | 36,064 | 0.0% | 0.02% | -46.7% |
Q2 2015 | $2,522,000 | -17.5% | 36,064 | -19.2% | 0.03% | -16.7% |
Q1 2015 | $3,056,000 | +2.4% | 44,614 | +9.6% | 0.04% | +12.5% |
Q4 2014 | $2,983,000 | +27.1% | 40,701 | +24.5% | 0.03% | +23.1% |
Q3 2014 | $2,347,000 | +0.4% | 32,704 | +1.2% | 0.03% | +13.0% |
Q2 2014 | $2,337,000 | -0.8% | 32,329 | +0.9% | 0.02% | -25.8% |
Q1 2014 | $2,357,000 | +0.8% | 32,029 | -4.8% | 0.03% | 0.0% |
Q4 2013 | $2,339,000 | -14.5% | 33,629 | -19.2% | 0.03% | -8.8% |
Q3 2013 | $2,735,000 | -6.4% | 41,629 | -1.3% | 0.03% | -15.0% |
Q2 2013 | $2,923,000 | – | 42,193 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |